| 0 (0%) | 06-28 18:07 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.16  |
1-year : | 2.44 |
| Resists | First : | 1.84 |
Second : | 2.08 |
| Pivot price | 1.71 |
|||
| Supports | First : | 1.46 |
Second : | 1.21 |
| MAs | MA(5) : | 1.64 |
MA(20) : | 1.75 |
| MA(100) : | 2.11 |
MA(250) : | 2.65 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 13.8 |
D(3) : | 27.3 |
| RSI | RSI(14): 38.4 |
|||
| 52-week | High : | 3.88 | Low : | 1.38 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ VNET ] has closed above bottom band by 4.2%. Bollinger Bands are 27.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.61 - 1.63 | 1.63 - 1.63 |
| Low: | 1.43 - 1.45 | 1.45 - 1.46 |
| Close: | 1.48 - 1.51 | 1.51 - 1.53 |
Thu, 14 Sep 2023
Training high school and community college students to be nurses and other health workers - Capitol Weekly
Mon, 17 Apr 2017
Zoetis (ZTS) Inks Agreement to Acquire Nexvet Biopharma - Yahoo Finance
Mon, 27 Mar 2017
CHTTi Offers Training in Hospitality Studies - The Voice St. Lucia
Fri, 10 Jun 2016
NCI to fund translational studies of immunotherapy for dogs with cancer - FiercePharma
Mon, 06 Jun 2016
Nexvet opens manufacturing facility as it preps for dog and cat trials - FiercePharma
Thu, 26 May 2016
Nexvet shares soar on positive trial of pain drug for cats - FiercePharma
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 257 (M) |
| Shares Float | 425 (M) |
| Held by Insiders | 7.5 (%) |
| Held by Institutions | 32.1 (%) |
| Shares Short | 8,530 (K) |
| Shares Short P.Month | 8,890 (K) |
| EPS | -0.25 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 39.09 |
| Profit Margin | -35.7 % |
| Operating Margin | -18 % |
| Return on Assets (ttm) | -0.3 % |
| Return on Equity (ttm) | -38.5 % |
| Qtrly Rev. Growth | 0.8 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 28.79 |
| EBITDA (p.s.) | 6.48 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -6 |
| PEG Ratio | -9.1 |
| Price to Book value | 0.03 |
| Price to Sales | 0.05 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|